Phone (303) 825-TUCC (8822)      Toll-Free (877) 825-8898
 

Urology News

Clinical advancements in the field of urology are featured in the news media every day. This section provides patients and physicians with the most up-to-date information on recent urologic advancements around the world.

* Please Note - TUCC does not necessarily advocate any of the treatment methods listed in the articles below. This news feed is provided as a resource for those interested in the latest urologic research occurring around the world.

  • February 3, 2012
    Clinical Data on OGX-427 Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer

    OncoGenex Announces Plans to Initiate a Phase 2 Study of OGX-427 in Combination with Zytiga® (abiraterone) in Castrate-Resistant Prostate Cancer

    OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today preliminary results from a Phase 2 prostate cancer study with its investigational compound OGX-427, which is designed to inhibit the production of Hsp27. Hsp27 is a cell-survival protein expressed in many types of cancers including prostate, bladder, breast and non-small cell lung cancer. Overexpression of Hsp27 is thought to be an important factor leading to the development of treatment resistance and is associated with negative clinical outcomes in patients with various tumor types.

  • February 2, 2012
    New study shows benefits of novel PSA velocity risk count testing for prostate cancer

    A new screening method for prostate cancer

    A new study by NYU Langone Medical Center and Northwestern University Feinberg School of Medicine shows novel PSA velocity (PSAV) risk count testing may provide a more effective way for physicians to screen men for clinically significant prostate cancer. The new study, published online by the British Journal of Urology International on February 1, 2012, shows the benefits of tracking a man's PSA levels over time to help doctors more accurately assess his risk of life-threatening prostate cancer.

     
  • February 1, 2012
    Gaining on Prostate Cancer - Drug Firms Advance Rapidly After Long Drought, but Treatments Are Pricey

    Drug companies have scored a string of recent successes against advanced prostate cancer, ending a long drought during which there seemed to be few weapons to combat the disease.

  • February 1, 2012
    UCSF discovery sheds light on how robust exercise may lower the risk of prostate cancer progression

     Vigorous exercise linked to gene activity in prostate

    Scientists at the University of California, San Francisco (UCSF) have identified nearly 200 genes in the healthy prostate tissue of men with low-grade prostate cancer that may help explain how physical activity improves survival from the disease.

  • January 31, 2012
    Exercise can improve health, quality of life for cancer survivors

    Exercise has been touted as a good way to help prevent certain diseases and conditions, but can it be useful after the fact? Yes, says a study, which suggests that a fitness regimen can enhance the health of patients following treatment.

    The paper analyzed 34 studies that looked at the effect of exercise on patients who had breast cancer, as well as other types of cancer, such as prostate and lung. The various studies included aerobic, resistance and strength workouts, the average length was 13 weeks and the average number of people in each trial was 93. Most of the control groups consisted of people who were sedentary or told to do no exercise.

  • January 24, 2012
    Prostate cancer growth slowed by commonly used drug

    A drug that is commonly used to treat men with enlarged prostates may also delay the growth of prostate cancer, according to a new study.

    The drug, dutasteride, works by blocking the conversion of testosterone to dihydrotestosterone, the male sex hormone implicated in the development of prostate cancer.

  • January 17, 2012
    UNC scientists collaborate to find first major genetic mutation associated with hereditary prostate cancer risk

    After a 20-year quest to find a genetic driver for prostate cancer that strikes men at younger ages and runs in families, researchers have identified a rare, inherited mutation linked to a significantly higher risk of the disease.

  • January 11, 2012
    A population-based study on the association between rheumatoid arthritis and erectile dysfunction

    Increased mortality in rheumatoid arthritis (RA) patients can be partly attributed to an accompanying increase in cardiovascular risk. On account of the increased cardiovascular risks and chronic inflammation, patients with RA may be more likely to contract other conditions with shared risk factors, such as erectile dysfunction (ED). However, although previous studies have reported sexual dysfunction among RA patients,1,,4 no study has explored the possible association between ED and RA to date. This study set out to investigate this putative association by using a population-based dataset and case–control design.                            

  • January 10, 2012
    Prevalence and correlates of erectile dysfunction in men on chronic haemodialysis: a multinational cross-sectional study

    Factors associated with erectile dysfunction in men on haemodialysis are incompletely identified due to suboptimal existing studies. We determined the prevalence and correlates of erectile dysfunction and identified combinations of clinical characteristics associated with a higher risk of erectile dysfunction using recursive partitioning and amalgamation (REPCAM) analysis

  • January 9, 2012
    Urinary retention due to benign enlarged prostate treated differently in 15 countries

    Men who experience a sudden inability to pass urine because of a non-cancerous enlarged prostate are hospitalised and treated differently depending on where they live, according to an international study published online by the urology journal BJUI.

Request an Appointment

TUCC is contracted with all major insurance companies. We look forward to providing you with clinically advanced, compassionate urologic care.

read more »